文献速递白血病

NPM1突变急性髓系白血病:从基础到临床

NPM1-mutated acute myeloid leukemia: from bench to bedside.
PubMed 文献 · Blood · 2020-01-01

NPM1突变是成人急性髓系白血病最常见的遗传学病变之一,约占三分之一病例,2017年WHO分类将其列为独立疾病实体。本文综述野生型NPM1在核仁中的新功能、NPM1与其他突变协同驱动AML的生物学与临床问题、NPM1突变克隆清除对治愈的意义、HOX基因表达的贡献,以及基于NPM1的可测量残留病评估和XPO1与menin-MLL抑制剂的临床前研究结果。

要点

  • NPM1突变约占成人AML的三分之一,导致NPM1突变蛋白异常胞质定位,2017年WHO分类将其列为独立实体。
  • NPM1与其他突变协同驱动AML并影响不同结局,清除NPM1突变克隆对实现AML治愈具有重要意义。
  • 本文讨论2017年WHO分类中未解决的诊断问题及NPM1突变在欧洲白血病Net遗传学风险分层中的重要性。

核心结论

  • NPM1突变是成人AML最常见的遗传学病变之一,约占三分之一病例,2017年WHO分类将其列为独立疾病实体。

研究设计与样本

  • 本文为综述,聚焦野生型NPM1在核仁中的新功能及NPM1突变AML相关的生物学与临床新问题。

主要发现

  • NPM1突变约占成人AML的三分之一病例,并决定性地导致NPM1突变蛋白异常胞质定位。
  • NPM1与其他突变协同驱动AML并导致不同结局,HOX基因表达对NPM1突变AML的发生有贡献。
  • 清除NPM1突变克隆对实现AML治愈具有重要意义,白血病前期克隆性造血持续存在可 predispose 至第二AML。

关键数值与推荐

  • 2017年WHO造血肿瘤分类将NPM1突变AML列为独立疾病实体。
  • 本文讨论NPM1突变在欧洲白血病Net遗传学风险分层框架中的重要性。
  • 本文讨论基于NPM1的可测量残留病评估用于治疗指导的价值与局限。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 2017年WHO髓系肿瘤分类中仍存在未解决的诊断问题。
  • 基于NPM1的可测量残留病评估用于治疗指导存在局限。
  • XPO1与menin-MLL抑制剂的结果来自临床前研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The nucleophosmin (NPM1) gene encodes for a multifunctional protein with prominent nucleolar localization that shuttles between nucleus and cytoplasm. NPM1 mutations represent the most common genetic lesion in adult acute myeloid leukemia (AML; about one third of cases), and they act deterministically to cause the aberrant cytoplasmic delocalization of NPM1 mutants. Because of its unique features, NPM1-mutated AML is recognized as a distinct entity in the 2017 World Health Organization (WHO) classification of hematopoietic neoplasms. Here, we focus on recently identified functions of wild-type NPM1 in the nucleolus and address new biological and clinical issues related to NPM1-mutated AML. The relevance of the cooperation between NPM1 and other mutations in driving AML with different outcomes is presented. We also discuss the importance of eradicating NPM1-mutated clones to achieve AML cure and the impact of preleukemic clonal hematopoiesis persistence in predisposing to second AML. The contribution of HOX genes' expression to the development of NPM1-mutated AML is also highlighted. Clinically, yet unsolved diagnostic issues in the 2017 WHO classification of myeloid neoplasms and the importance of NPM1 mutations in defining the framework of European LeukemiaNet genetic-based risk stratification are discussed. Finally, we address the value and limits of NPM1-based measurable residual disease assessment for treatment guidance and present the results of promising preclinical studies with XPO1 and menin-MLL inhibitors.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Falini B, Brunetti L, Sportoletti P, et al. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood. 2020. PMID: 32609823. doi:10.1182/blood.2019004226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。